Sugi Predict

Sugi Predict / Compounds / SCHEMBL2326164

SCHEMBL2326164

SCHEMBL2326164

Cc1cc(B2OC(C)(C)C(C)(C)O2)cc(Cl)n1

nearest known ligand 0.38

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 13/20 0.38
▸ LIPG Q9Y5X9 13/20 0.38
▸ IRAK4 Q9NWZ3 1/20 0.37
▸ FFAR1 O14842 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ EGFR P00533 1/20 0.32
▸ SNCA P37840 1/20 0.32
▸ CA1 P00915 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ CA9 Q16790 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29384616 1.00 LPL (0.38) LPLLIPGIRAK4FFAR1LMNA
SCHEMBL2370200 0.89 LPL (0.42) LPLLIPGIRAK4FFAR1EGFR
SCHEMBL4671691 0.87 LPL (0.43) LPLLIPGIRAK4FFAR1SNCA
SCHEMBL3028464 0.81 LPL (0.42) LPLLIPGIRAK4FFAR1EGFR
SCHEMBL30541765 0.81 LPL (0.42) LPLLIPGIRAK4FFAR1EGFR
SCHEMBL3027012 0.79 SNCA (0.39) LPLLIPGFFAR1LMNAEGFR
SCHEMBL38657929 0.79 SNCA (0.39) LPLLIPGFFAR1LMNAEGFR
SCHEMBL17667853 0.79 LPL (0.38) LPLLIPGIRAK4FFAR1SNCA
SCHEMBL16534924 0.79 LPL (0.43) LPLLIPGIRAK4FFAR1SNCA
SCHEMBL2186152 0.79 NOS3 (0.44) LPLLIPGIRAK4FFAR1SNCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617796-B2 Antagonists of the adenosine A2a receptor JANSSEN PHARMACEUTICA NV (BE) 2026-05-05 — — US disclosed
EP-4620533-A2 ANTAGONIST COMPOUNDS Adorx therapeutics Limited (GB) 2025-09-24 — — EP disclosed
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer ARTIOS PHARMA LIMITED (GB) 2025-07-15 — — US disclosed
US-20250206729-A1 DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2025-06-26 — — US disclosed
EP-4188924-B1 ANTAGONIST COMPOUNDS ADORX THERAPEUTICS LTD (GB) 2025-06-18 — — EP disclosed
US-20250122203-A1 ADENOSINE RECEPTOR ANTAGONISTS CROSSIGNAL THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-12065444-B2 Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists CROSSIGNAL THERAPEUTICS, INC. (US) 2024-08-20 — — US disclosed
US-12054472-B2 1,2,4-triazine-4-amine derivatives NXERA PHARMA UK LIMITED (GB) 2024-08-06 — — US disclosed
CN-118317965-A Adenosine receptor antagonists 交信医药研发公司 2024-07-09 — — CN disclosed
CN-113166119-B Substituted aryl compound and preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2024-01-05 — — CN disclosed
US-20130079326-A1 N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 MERCK SHARP & DOHME CORP. 2013-03-28 — — US disclosed
US-20130079326-A1 N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 MERCK SHARP & DOHME CORP. 2013-03-28 — — US disclosed
US-20130029963-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES HEPTARES THERAPEUTICS LIMITED (GB) 2013-01-31 — — US disclosed
EP-2531492-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES Heptares Therapeutics Limited (GB) 2012-12-12 — — EP disclosed
WO-2011149874-A2 N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 SCHERING CORPORATION (US) 2011-12-01 — — WO disclosed
WO-2011149874-A2 N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 SCHERING CORPORATION (US) 2011-12-01 — — WO disclosed
WO-2011095625-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES HEPTARES THERAPEUTICS LIMITED (GB) 2011-08-11 — — WO disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 — — EP disclosed
EP-1562934-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-08-17 — — EP disclosed
WO-2004046133-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206729-A1 DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF BRAF, MAP2K2, MAP2K1 LPL 4799/4885LIPG 3922/4885IRAK4 2245/4885
US-12617796-B2 Antagonists of the adenosine A2a receptor ADORA2A, ADORA2B, ADORA3 LPL 3472/4885LIPG 3636/4885IRAK4 2309/4885
US-20250122203-A1 ADENOSINE RECEPTOR ANTAGONISTS ADORA2A, ADORA1, ADORA3 LPL 1261/4885LIPG 1075/4885IRAK4 1569/4885
US-12054472-B2 1,2,4-triazine-4-amine derivatives ADORA2A, ADORA2B, ADORA1 LPL 4561/4885LIPG 4635/4885IRAK4 1844/4885
US-12065444-B2 Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists ADORA2A, ADORA1, P2RX5 LPL 2372/4885LIPG 3397/4885IRAK4 1004/4885
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer SDHA, DPYD, TP53 LPL 4213/4885LIPG 2682/4885IRAK4 4424/4885
US-20130029963-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES ADORA2B, ADORA2A, ADORA1 LPL 4158/4885LIPG 3924/4885IRAK4 1958/4885
US-20130079326-A1 N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 PDPK1, PDK1, PDK3 LPL 4630/4885LIPG 4458/4885IRAK4 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.